MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the hematology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
Prof Dr Michel Delforge, UZ Leuven, was one of the experts contributing to the first version of the ESMO-Magnitude of Clinical Benefit Scale for hematological malignancies (ESMO-MCBS:H). In this video,
Dr. Gustav Cederquist from the Memorial Sloan Kettering Cancer Center, New Yorkevaluated the potential of brain radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma.
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma is associated with poor outcomes necessitating the identification of high-risk patients. To refine CNS risk stratification, a better understanding of
Enteropathy associated T-cell lymphoma is a rare peripheral T-cell lymphoma with a poor prognosis. Dr. Frederik Meeuwes, hematologist from the Treant hospital in Emmen presented a population-based cohort study on
Vera De Jonge, PhD student from the VUMC, Amsterdam and Joanna Bult, PhD student from the University Medical Center Groningen assessed the impact of a rearrangement of the MYC oncogene
Dr Jason Westin, hematologist at Texas MD Anderson Cancer Center, Houston gives insight into the overall survival findings from the ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or
Prof. Stephan Stilgenbauer, hematologist at the Ulm University in Germany shares his view on the role of BTK-inhibitors in B-cell malignancies. He discusses the potential of second-generation BTK-inhibitors and provides
Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the SELENE study for which she was one of the investigators. This phase 3 study evaluated ibrutinib plus bendamustine-rituximab
